- Home
- CERO vs RDHL Comparison
CERO vs RDHL Comparison
Compare CERO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- RDHL
- Stock Information
- Founded
- CERO 2017
- RDHL 2009
- Country
- CERO United States
- RDHL Israel
- Employees
- CERO N/A
- RDHL N/A
- Industry
- CERO
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- RDHL Health Care
- Exchange
- CERO Nasdaq
- RDHL Nasdaq
- Market Cap
- CERO 8.4M
- RDHL 6.8M
- IPO Year
- CERO N/A
- RDHL N/A
- Fundamental
- Price
- CERO $0.96
- RDHL $2.60
- Analyst Decision
- CERO
- RDHL
- Analyst Count
- CERO 0
- RDHL 0
- Target Price
- CERO N/A
- RDHL N/A
- AVG Volume (30 Days)
- CERO 473.6K
- RDHL 177.8K
- Earning Date
- CERO 03-25-2025
- RDHL 04-07-2025
- Dividend Yield
- CERO N/A
- RDHL N/A
- EPS Growth
- CERO N/A
- RDHL N/A
- EPS
- CERO N/A
- RDHL N/A
- Revenue
- CERO N/A
- RDHL $3,707,000.00
- Revenue This Year
- CERO N/A
- RDHL $224.90
- Revenue Next Year
- CERO N/A
- RDHL $82.69
- P/E Ratio
- CERO N/A
- RDHL N/A
- Revenue Growth
- CERO N/A
- RDHL N/A
- 52 Week Low
- CERO $0.93
- RDHL $2.57
- 52 Week High
- CERO $376.00
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- CERO 26.37
- RDHL 15.82
- Support Level
- CERO $1.26
- RDHL $2.57
- Resistance Level
- CERO $1.54
- RDHL $3.47
- Average True Range (ATR)
- CERO 0.15
- RDHL 0.47
- MACD
- CERO 0.06
- RDHL -0.06
- Stochastic Oscillator
- CERO 3.51
- RDHL 0.94
Stock Price Comparison Chart: CERO vs RDHL
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.